Lindus Health launches Medical Device CRO offering.
READ MORE
NEW YORK, NY and SEATTLE – June 4, 2024 – Lindus Health, the “anti-CRO” running radically faster, more reliable clinical trials for life science pioneers, and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced a new collaboration that will reduce patient burden in clinical trials requiring blood collection. Lindus Health will adopt Tasso’s virtually painless remote blood collection technology as an option for sponsors looking to enable simple, more cost-effective remote blood collection while conducting their clinical trials. This innovative method will allow participants to collect simple blood samples themselves at home without the need for a mobile phlebotomist or nurse.
Logistical factors are common barriers to study participation. The inclusion of Tasso minimizes these by reducing, and sometimes even eliminating, lengthy study visits and travel to and from physical sites with their solution that allows clinical trial participants to collect blood from the comfort of their own homes, without the added expense and logistics of mobile phlebotomy/nursing. Tasso remote blood sampling technologies have the capabilities to increase the reach and diversity of clinical trials whilst reducing patient burden and associated dropout rates. Clinical trial participants will receive Tasso’s blood collection device along with prepaid shipping materials to easily ship their samples for analysis.
Tasso’s clinical grade blood collection technology is preferred by 9 out of 10 participants over a fingerstick or phlebotomy. By offering a more convenient way of performing blood draws in clinical research, sponsors can anticipate higher rates of patient recruitment and retention in their studies, ultimately reducing timelines to achieve enrollment targets.
"Partnering with Tasso provides Lindus Health with a cutting-edge tool for remote blood collection, significantly expediting the clinical trial process,” said Michael Young, Co-Founder of Lindus Health. “This collaboration enables us to design more flexible and patient-centric trials, ensuring greater convenience and participation. Together, we are accelerating the delivery of new treatments to patients, transforming the landscape of medical research."
“Patients are at the heart of clinical trials,” said Ben Casavant, PhD, CEO and Co-Founder of Tasso. “Making blood collection a better experience can bolster patient engagement, ultimately leading to trials that recruit and complete faster. We are pleased to partner with fellow innovator Lindus Health to accelerate life-saving clinical studies.”
The integration of Tasso’s at-home blood collection into Lindus Health’s sample collection services, enables enhanced, more cost-effective data collection and encourages the adoption of patient-centric practices in clinical research.
Lindus Health is an anti-CRO running radically faster and more reliable trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 30 million Electronic Health Records.
Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint by handling the end-to-end execution of clinical studies, including design, patient recruitment, clinical data capture, monitoring and project management.
To date, Lindus Health has delivered more than 90 trials across the US, UK and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $24M from investors including Peter Thiel, CREANDUM, Firstminute Capital, Presight Capital, Seedcamp, Hambro Perks, Amino Collective and Calm/Storm.
Tasso is an emerging healthcare technology company that is transforming the traditional blood collection paradigm with a patient-centric approach. The company’s devices enable simple, convenient, and virtually painless blood collection for users. Tasso technology has the power to bring healthcare anywhere, any time. Headquartered in Seattle, Washington, Tasso is privately held and funded by grants, investments, and co-development deals with various industry leaders. For more information, please visit www.tassoinc.com.
Lindus Health
Jodi Perkins Amendola
Tasso, Inc.
Dina Schneider
(206) 822-4186 x1016
CLEO Appoints CRO to Manage U.S. Ovarian Cancer Clinical Trials
Announcing our recent collaboration with CLEO Diagnostics for an ovarian cancer detection clinical trial.
